Xenetic Biosciences opened lower at $1.86, compared with its previous close of $1.87. In the last trading session, the stock traded between $1.65 and $1.87. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Xenetic Biosciences is now worth
$ 10.12
Resulting in a loss of
$ 89.88 (89.88%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.18 (-9.44%)
Day High
$1.87
Day Low
$1.65
Day Open
$1.86
Prev Close
$1.87
Volume
21,508
1W Return
-16.87%
1M Return
-20.84%
3M Return
-46.52%
6M Return
-46.18%
1Y Return
-38.10%
Fundamentals
Market Cap ($ Mn)
4
PE Ratio
-
PB Ratio
1.54
PEG Ratio
-
ROE
-49.79%
ROCE
-52.52%
EPS (TTM)
$-0.41
Investment Returns
1 Week
-16.87%
1 Month
-20.84%
3 Months
-46.52%
6 Months
-46.18%
9 Months
-21.03%
Financials
Quarterly
All values in $ Mn
0.6
Mar 25
0.6
Jun 25
1.0
Sep 25
0.8
Dec 25
0.8
Mar 26
0.7
Jun 26
Updates
15Oct
Xenetic partner doses first patient in LBCL trial in Israel
PeriNess Ltd. dosed the first patient in an LBCL clinical trial in Israel. Study evaluates systemic recombinant human DNase with anti-CD19 CAR T-cell therapy. Trial conducted at Tel Aviv Sourasky University Medical Center (Ichilov Center). Xenetic Biosciences confirmed the update from its collaboration partner.
28 days ago
16Sep
Xenetic, Santersus merge to create NET-targeting biotech firm
Xenetic Biosciences and Santersus AG enter definitive all-stock merger agreement. Combined entity to trade as Santersus Bio, Inc. under ticker SNTS on Nasdaq. Santersus shareholders to own ~85% of pro forma company; Xenetic retains ~15%. Merger creates clinical-stage firm targeting neutrophil extracellular traps (NETs). Pipeline covers sepsis, SLE, liver transplantation, and B-cell lymphoma.
1mo ago
7Aug
Xenetic Biosciences Q2 EPS improves to $(0.41), sales rise 12%
Xenetic Biosciences posted Q2 EPS of $(0.41) and sales of $660.6K, up 12% YoY. Despite improved per-share metrics, net loss widened to $0.9M amid a 64% surge in G&A expenses linked to strategic reviews.
